Sephience drives strong revenue growth and global expansion, supported by robust clinical data and a broad rare disease pipeline. Votoplam and vatiquinone advance in late-stage trials, while innovative R&D platforms position the company for long-term success.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.